Metabolomic and transcriptomic profiling of human K- ras oncogene transgenic rats with pancreatic ductal adenocarcinomas-Reference-Cited by-同舟云学术

Metabolomic and transcriptomic profiling of human K- ras oncogene transgenic rats with pancreatic ductal adenocarcinomas

Published:2013-02-07 Issue:6 Volume:34 Page:1251-1259
ISSN:1460-2180
Container-title:Carcinogenesis
language:en
Short-container-title:

Author:

Yabushita Setsuko,Fukamachi Katsumi,Tanaka Hajime,Fukuda Takako,Sumida Kayo,Deguchi Yoshihito,Mikata Kazuki,Nishioka Kazuhiko,Kawamura Satoshi,Uwagawa Satoshi,Suzui Masumi,Alexander David B.,Tsuda Hiroyuki

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,General Medicine

Link

http://academic.oup.com/carcin/article-pdf/34/6/1251/17293133/bgt053.pdf

Reference20 articles.

1. Cancer statistics, 2003;Jemal;CA Cancer J. Clin.,2003

2. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature;Akdogan;Tumori.,2001

3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer;Ni;Eur. J. Surg. Oncol.,2005

4. CA 19-9 as a marker for gastrointestinal cancers: a review;Duffy;Ann. Clin. Biochem.,1998

5. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas;Ueda;Carcinogenesis.,2006

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LncRNA FAM83H-AS1 Contributes to the Radio-resistance and Proliferation in Liver Cancer through Stability FAM83H Protein;Recent Patents on Anti-Cancer Drug Discovery;2024-08

2. Metabolite-Based Biosignature of Pancreatic Cancer;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

3. Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model;Frontiers in Molecular Biosciences;2022-08-25

4. Correlation of miR-31 and miR-373 expression with KRAS mutations and its impact on prognosis in colorectal cancer;Journal of the Egyptian National Cancer Institute;2022-08-22

5. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets;Cancer and Metastasis Reviews;2021-12